|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FAM98A |
Gene summary for FAM98A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FAM98A | Gene ID | 25940 |
| Gene name | family with sequence similarity 98 member A | |
| Gene Alias | FAM98A | |
| Cytomap | 2p22.3 | |
| Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | B4DT23 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 25940 | FAM98A | LZE4T | Human | Esophagus | ESCC | 1.62e-08 | 2.34e-01 | 0.0811 |
| 25940 | FAM98A | LZE22T | Human | Esophagus | ESCC | 7.92e-03 | 1.69e-01 | 0.068 |
| 25940 | FAM98A | LZE24T | Human | Esophagus | ESCC | 3.53e-08 | 1.81e-01 | 0.0596 |
| 25940 | FAM98A | LZE21T | Human | Esophagus | ESCC | 2.21e-04 | 1.20e-01 | 0.0655 |
| 25940 | FAM98A | LZE6T | Human | Esophagus | ESCC | 2.40e-02 | 2.85e-02 | 0.0845 |
| 25940 | FAM98A | P1T-E | Human | Esophagus | ESCC | 1.48e-04 | 1.30e-01 | 0.0875 |
| 25940 | FAM98A | P2T-E | Human | Esophagus | ESCC | 4.64e-20 | 3.14e-01 | 0.1177 |
| 25940 | FAM98A | P4T-E | Human | Esophagus | ESCC | 5.96e-19 | 5.43e-01 | 0.1323 |
| 25940 | FAM98A | P5T-E | Human | Esophagus | ESCC | 1.66e-11 | 1.74e-01 | 0.1327 |
| 25940 | FAM98A | P8T-E | Human | Esophagus | ESCC | 3.10e-08 | 1.28e-01 | 0.0889 |
| 25940 | FAM98A | P9T-E | Human | Esophagus | ESCC | 1.28e-16 | 1.61e-01 | 0.1131 |
| 25940 | FAM98A | P10T-E | Human | Esophagus | ESCC | 2.77e-11 | 1.93e-01 | 0.116 |
| 25940 | FAM98A | P11T-E | Human | Esophagus | ESCC | 2.36e-16 | 5.08e-01 | 0.1426 |
| 25940 | FAM98A | P12T-E | Human | Esophagus | ESCC | 1.62e-10 | 2.09e-01 | 0.1122 |
| 25940 | FAM98A | P15T-E | Human | Esophagus | ESCC | 8.21e-12 | 2.30e-01 | 0.1149 |
| 25940 | FAM98A | P16T-E | Human | Esophagus | ESCC | 3.82e-12 | 2.68e-01 | 0.1153 |
| 25940 | FAM98A | P17T-E | Human | Esophagus | ESCC | 3.12e-09 | 2.19e-01 | 0.1278 |
| 25940 | FAM98A | P19T-E | Human | Esophagus | ESCC | 2.41e-09 | 7.67e-01 | 0.1662 |
| 25940 | FAM98A | P20T-E | Human | Esophagus | ESCC | 1.74e-11 | 2.64e-01 | 0.1124 |
| 25940 | FAM98A | P21T-E | Human | Esophagus | ESCC | 1.34e-24 | 3.61e-01 | 0.1617 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00434143 | Esophagus | ESCC | macromolecule methylation | 199/8552 | 316/18723 | 3.44e-10 | 9.57e-09 | 199 |
| GO:00322592 | Esophagus | ESCC | methylation | 222/8552 | 364/18723 | 2.26e-09 | 5.09e-08 | 222 |
| GO:000647914 | Esophagus | ESCC | protein methylation | 115/8552 | 181/18723 | 9.07e-07 | 1.16e-05 | 115 |
| GO:000821314 | Esophagus | ESCC | protein alkylation | 115/8552 | 181/18723 | 9.07e-07 | 1.16e-05 | 115 |
| GO:003134616 | Esophagus | ESCC | positive regulation of cell projection organization | 201/8552 | 353/18723 | 1.19e-05 | 1.11e-04 | 201 |
| GO:00315299 | Esophagus | ESCC | ruffle organization | 39/8552 | 56/18723 | 2.44e-04 | 1.51e-03 | 39 |
| GO:00971789 | Esophagus | ESCC | ruffle assembly | 32/8552 | 44/18723 | 2.50e-04 | 1.54e-03 | 32 |
| GO:006049118 | Esophagus | ESCC | regulation of cell projection assembly | 110/8552 | 188/18723 | 2.60e-04 | 1.58e-03 | 110 |
| GO:012003218 | Esophagus | ESCC | regulation of plasma membrane bounded cell projection assembly | 108/8552 | 186/18723 | 4.37e-04 | 2.46e-03 | 108 |
| GO:01200347 | Esophagus | ESCC | positive regulation of plasma membrane bounded cell projection assembly | 64/8552 | 105/18723 | 1.15e-03 | 5.70e-03 | 64 |
| GO:19000277 | Esophagus | ESCC | regulation of ruffle assembly | 21/8552 | 31/18723 | 1.10e-02 | 3.70e-02 | 21 |
| GO:00434141 | Liver | HCC | macromolecule methylation | 183/7958 | 316/18723 | 2.00e-08 | 4.72e-07 | 183 |
| GO:0032259 | Liver | HCC | methylation | 206/7958 | 364/18723 | 3.35e-08 | 7.53e-07 | 206 |
| GO:00064792 | Liver | HCC | protein methylation | 111/7958 | 181/18723 | 2.36e-07 | 4.18e-06 | 111 |
| GO:00082132 | Liver | HCC | protein alkylation | 111/7958 | 181/18723 | 2.36e-07 | 4.18e-06 | 111 |
| GO:003134611 | Liver | HCC | positive regulation of cell projection organization | 193/7958 | 353/18723 | 2.28e-06 | 3.08e-05 | 193 |
| GO:006049112 | Liver | HCC | regulation of cell projection assembly | 101/7958 | 188/18723 | 1.20e-03 | 6.69e-03 | 101 |
| GO:012003212 | Liver | HCC | regulation of plasma membrane bounded cell projection assembly | 100/7958 | 186/18723 | 1.23e-03 | 6.81e-03 | 100 |
| GO:003152911 | Liver | HCC | ruffle organization | 34/7958 | 56/18723 | 4.54e-03 | 1.96e-02 | 34 |
| GO:01200344 | Liver | HCC | positive regulation of plasma membrane bounded cell projection assembly | 58/7958 | 105/18723 | 5.66e-03 | 2.36e-02 | 58 |
| Page: 1 2 3 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FAM98A | SNV | Missense_Mutation | rs201777834 | c.625C>A | p.Gln209Lys | p.Q209K | Q8NCA5 | protein_coding | tolerated(0.3) | possibly_damaging(0.703) | TCGA-A8-A06R-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |
| FAM98A | SNV | Missense_Mutation | novel | c.791N>A | p.Ser264Tyr | p.S264Y | Q8NCA5 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FAM98A | SNV | Missense_Mutation | c.1157N>C | p.Gly386Ala | p.G386A | Q8NCA5 | protein_coding | tolerated(0.28) | possibly_damaging(0.537) | TCGA-AN-A04D-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| FAM98A | SNV | Missense_Mutation | c.529G>A | p.Glu177Lys | p.E177K | Q8NCA5 | protein_coding | tolerated(0.08) | benign(0.12) | TCGA-AN-A0FS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| FAM98A | SNV | Missense_Mutation | c.1208N>C | p.Gly403Ala | p.G403A | Q8NCA5 | protein_coding | deleterious_low_confidence(0.01) | benign(0.177) | TCGA-AO-A124-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| FAM98A | SNV | Missense_Mutation | rs201777834 | c.625N>A | p.Gln209Lys | p.Q209K | Q8NCA5 | protein_coding | tolerated(0.3) | possibly_damaging(0.703) | TCGA-BH-A0HO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
| FAM98A | SNV | Missense_Mutation | rs201777834 | c.625N>A | p.Gln209Lys | p.Q209K | Q8NCA5 | protein_coding | tolerated(0.3) | possibly_damaging(0.703) | TCGA-BH-A0HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
| FAM98A | SNV | Missense_Mutation | c.1514N>C | p.Tyr505Ser | p.Y505S | Q8NCA5 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.485) | TCGA-BH-A18L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| FAM98A | SNV | Missense_Mutation | rs201777834 | c.625N>A | p.Gln209Lys | p.Q209K | Q8NCA5 | protein_coding | tolerated(0.3) | possibly_damaging(0.703) | TCGA-BH-A1F8-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| FAM98A | SNV | Missense_Mutation | rs763293643 | c.229N>A | p.Leu77Ile | p.L77I | Q8NCA5 | protein_coding | tolerated(0.07) | probably_damaging(0.994) | TCGA-D8-A1J9-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |